UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities ~~ExchangeAct~~Exchange Act of 1934

~~February~~March 627, 2026

Date of Report (Date of earliest event reported)

Enveric Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38286

95-4484725

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

Enveric Biosciences, Inc.

245 First Street,  Riverview II, 18th Floor ~~Cambridge~~, ~~MA, 02142~~

Cambridge, MA 00000

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (617) 444-8400

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the ~~SecuritiesAct~~Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the ~~ExchangeAct~~Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the ~~ExchangeAct~~Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the ~~ExchangeAct~~Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		ENVB		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities ~~ExchangeAct~~Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ~~ExchangeAct~~Exchange Act. ☐

Item 82.0102 ~~Other~~Results ~~Events~~of Operations and Financial Condition.

On ~~February~~March 627, 2026, Enveric Biosciences, Inc. ~~(the~~issued ~~“Company”) filed~~ a ~~prospectus~~press ~~supplement~~release ~~(the~~providing ~~“Prospectus~~a ~~Supplement”) to~~corporate ~~register~~update anand ~~additional~~announcing ~~$1,346,000 of shares (the “Shares”) of~~ its ~~common~~financial ~~stock, par value $0.01 per share (“Common~~results ~~Stock”),~~for ~~issuable pursuant to~~ the Atfourth ~~The~~quarter ~~Market Offering Agreement between the Company~~ and ~~H.C.~~year ~~Wainwright~~ended &December ~~Co.~~31, ~~LLC (the “Sales Agent”), dated April 9,~~ 2025 ~~(the “ATM Agreement”)~~. ~~Prior~~A tocopy ~~the date hereof, the Company has sold an aggregate~~ of ~~$1,853,878.34~~this ~~shares~~press ofrelease ~~its Common Stock through the Sales Agent under the ATM Agreement. An opinion regarding the legality of the Shares issuable under the ATM Agreement and covered by the Prospectus Supplement~~ is ~~filed~~furnished as Exhibit 599.1 tohereto ~~this~~and ~~Current~~is ~~Report~~incorporated onherein ~~Form~~by ~~8-K~~reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		~~Exhibits~~Description
5.1		Legal Opinion of Greenberg Traurig, LLP
99.1		Press Release, dated March 27, 2026 (furnished pursuant to Item 2.02)
23.1		Consent of Greenberg Traurig, LLP (contained in Exhibit 5.1)
104		Cover Page Interactive Data File (formatted as Inline XBRL)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:February 6, 2026	ENVERIC BIOSCIENCES, INC.
Date: March 27, 2026	ENVERIC BIOSCIENCES, INC.
	By:	/s/ Joseph Tucker
		Joseph Tucker, Ph.D.
		Chief Executive Officer

Filing Compare · Enveric Biosciences, Inc.